E
Esperanza Herreros
Researcher at GlaxoSmithKline
Publications - 45
Citations - 2178
Esperanza Herreros is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Plasmodium falciparum & Gametocyte. The author has an hindex of 22, co-authored 45 publications receiving 1928 citations. Previous affiliations of Esperanza Herreros include Medicines for Malaria Venture.
Papers
More filters
Journal ArticleDOI
Quinolone-3-Diarylethers: A New Class of Antimalarial Drug
Aaron Nilsen,Alexis N. LaCrue,Karen L. White,Isaac P. Forquer,R. Matthew Cross,Jutta Marfurt,Michael W. Mather,Michael J. Delves,David M. Shackleford,Fabián E. Sáenz,Joanne M. Morrisey,Jessica Anne Steuten,Tina Mutka,Yuexin Li,Grennady Wirjanata,Eileen Ryan,Sandra Duffy,Jane X. Kelly,Boni F. Sebayang,Anne-Marie Zeeman,Rintis Noviyanti,Robert E. Sinden,Clemens H. M. Kocken,Ric N. Price,Ric N. Price,Vicky M. Avery,Iñigo Angulo-Barturen,María Belén Jiménez-Díaz,Santiago Ferrer,Esperanza Herreros,Laura M. Sanz,Francisco-Javier Gamo,Ian Bathurst,Jeremy N. Burrows,Peter Siegl,R. Kiplin Guy,Rolf W. Winter,Akhil B. Vaidya,Susan A. Charman,Dennis E. Kyle,Roman Manetsch,Michael K. Riscoe +41 more
TL;DR: ELQ-300, a 4(1H)-quinolone-3-diarylether, which targets the liver and blood stages, including the forms that are crucial to disease transmission (gametocytes, zygotes, and ookinetes), has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria.
Journal ArticleDOI
Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence “transmission blocking”assay
Joël Lelièvre,Maria Jesus Almela,Sonia Lozano,Celia Miguel,Virginia Franco,Didier Leroy,Esperanza Herreros +6 more
TL;DR: An efficient method to produce and purify mature gametocytes in vitro and an assay to determine the activity of antimalarial drugs based on the intracellular ATP content of purified stage IV–Vgametocytes after 48 h of drug exposure in 96/384-well microplates are designed.
Journal ArticleDOI
Male and Female Plasmodium falciparum Mature Gametocytes Show Different Responses to Antimalarial Drugs
Michael J. Delves,Andrea Ruecker,Ursula Straschil,Joël Lelièvre,Sara R. Marques,María José López-Barragán,Esperanza Herreros,Robert E. Sinden +7 more
TL;DR: These findings show firstly that the antimalarial responses of male and female gametocytes differ and secondly that the mature male gametocyte should be considered a more vulnerable target than the femalegametocyte for transmission-blocking drugs.
Journal ArticleDOI
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes.
Iñigo Angulo-Barturen,María Belén Jiménez-Díaz,Teresa Mulet,Joaquín Rullas,Esperanza Herreros,Santiago Ferrer,Elena Jimenez,Alfonso Mendoza,Javier Regadera,Philip J. Rosenthal,Ian Bathurst,David L. Pompliano,Federico Gómez de las Heras,Domingo Gargallo-Viola +13 more
TL;DR: Using this model, a reproducible assay of antimalarial activity useful for drug discovery is implemented and validated and demonstrates that P. falciparum contains clones able to grow reproducibly in mice engrafted with human erythrocytes without the use of myeloablative methods.
Journal ArticleDOI
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.
Christel Brunschwig,Nina Lawrence,Dale Taylor,Efrem Abay,Mathew Njoroge,Gregory S. Basarab,Claire Le Manach,Tanya Paquet,Diego Gonzàlez Cabrera,Aloysius T. Nchinda,Carmen de Kock,Lubbe Wiesner,Paolo Denti,David Waterson,Benjamin Blasco,Didier Leroy,Michael J Witty,Cristina Donini,James Duffy,Sergio Wittlin,Sergio Wittlin,Karen L. White,Susan A. Charman,María Belén Jiménez-Díaz,Iñigo Angulo-Barturen,Esperanza Herreros,Francisco-Javier Gamo,Rosemary Rochford,Dalu Mancama,Theresa L. Coetzer,Mariëtte van der Watt,Janette Reader,Lyn-Marie Birkholtz,Kennan C. Marsh,Suresh Solapure,John E. Burke,Jacob A. McPhail,Manu Vanaerschot,David A. Fidock,Paul V. Fish,Peter Siegl,Dennis A. Smith,Grennady Wirjanata,Rintis Noviyanti,Ric N. Price,Ric N. Price,Jutta Marfurt,Kigbafori D. Silué,Leslie J. Street,Kelly Chibale,Kelly Chibale +50 more
TL;DR: UCT943, based on the combined preclinical data, has the potential to form part of a single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent, and block the transmission of malaria.